Results 231 to 240 of about 234,795 (273)
Some of the next articles are maybe not open access.
Briakinumab for the Treatment of Plaque Psoriasis
BioDrugs, 2012Psoriasis is a chronic inflammatory skin disorder affecting approximately 2% of individuals worldwide. An improved understanding of the pathogenesis of psoriasis has led to the development of targeted biologic therapies. Briakinumab (ABT-874) is a recombinant human antibody that blocks the biological activity of the cytokines interleukin (IL)-12 and IL-
Pawel, Traczewski, Lidia, Rudnicka
openaire +2 more sources
Comorbidities in patients with palmoplantar plaque psoriasis
Journal of the American Academy of Dermatology, 2021Psoriasis has been shown to be associated with several comorbidities. Whether the palmoplantar subtype of plaque psoriasis carries similar risks for comorbidities as generalized plaque psoriasis remains to be defined.To examine the association between palmoplantar plaque psoriasis and comorbidities known to be associated with generalized plaque ...
Eli Sprecher
exaly +3 more sources
Hyperuricemia in Patients with Chronic Plaque Psoriasis
Drug Development Research, 2014Abstract Postmarketing Phase IV Psoriasis is frequently associated with obesity, which may favor the development of hyperuricemia. Hyperuricemia predisposes patients to gout arthritis and is an emerging cardiovascular risk factor. In this study, we investigated the prevalence of hyperuricemia and serum uric acid (SUA) levels in psoriatic ...
GISONDI, Paolo +3 more
openaire +6 more sources
Secukinumab for treating plaque psoriasis
Expert Opinion on Biological Therapy, 2015Plaque psoriasis is a chronic inflammatory disease that can result in significant physical, psychological and quality of life impairments. Until recently, biologic treatment for psoriasis was limited to tumor necrosis factor-α inhibitors and an interleukin (IL)-12/23 p40 subunit inhibitor. Newly developed biologics targeting the pro-inflammatory IL-17A
Brooke, Rothstein, Alice, Gottlieb
openaire +2 more sources
Deucravacitinib (Sotyktu) for Plaque Psoriasis
The Medical Letter on Drugs and Therapeutics, 2023The FDA has approved deucravacitinib (Sotyktu – BMS), an oral tyrosine kinase 2 (TYK2) inhibitor, for once-daily treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Deucravacitinib is the first selective TYK2 inhibitor to be approved in the US for any indication.
openaire +2 more sources
Practice Nursing, 2008
Psoriasis is a common condition of the skin that affects 1–2% of the UK population (British Association of Dermatologists (BAD), 2006). The effect on those who have psoriasis can be profound, not only in symptoms, but also in the effect on their social lives, both at home and at work.
openaire +1 more source
Psoriasis is a common condition of the skin that affects 1–2% of the UK population (British Association of Dermatologists (BAD), 2006). The effect on those who have psoriasis can be profound, not only in symptoms, but also in the effect on their social lives, both at home and at work.
openaire +1 more source
Bimekizumab versus Secukinumab in Plaque Psoriasis
New England Journal of Medicine, 2021Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with secukinumab, which selectively inhibits interleukin-17A alone, in patients with moderate-to-severe plaque psoriasis have not been extensively examined.In this phase 3b trial, we randomly ...
Reich, Kristian +12 more
openaire +2 more sources
Chronic plaque psoriasis: an overview
Nursing Standard, 2002Psoriasis can have a dramatic effect on patients' lives. Karina Jackson describes the symptoms, possible causes and treatment options and outlines the role of the nurse in assessment and ongoing management.
openaire +2 more sources
The Medical Letter on Drugs and Therapeutics
Mild to moderate plaque psoriasis can be treated with topical drugs and phototherapy. Patients with moderate to severe disease generally require systemic therapy. Guidelines for the treatment of psoriasis with topical therapy, phototherapy, and systemic drugs have recently been published.
openaire +2 more sources
Mild to moderate plaque psoriasis can be treated with topical drugs and phototherapy. Patients with moderate to severe disease generally require systemic therapy. Guidelines for the treatment of psoriasis with topical therapy, phototherapy, and systemic drugs have recently been published.
openaire +2 more sources
Adalimumab: A Review in Chronic Plaque Psoriasis
Drugs, 2015Adalimumab (Humira(®)) is a fully human monoclonal antibody against tumour necrosis factor (TNF), formulated for subcutaneous administration. It is well established in the treatment of adults with moderate-to-severe chronic plaque psoriasis and has recently received approval in the EU for the treatment of severe chronic plaque psoriasis in children and
Celeste B, Burness, Kate, McKeage
openaire +2 more sources